ASC
Ardmore Shipping Corporation · Industrials
15.27
2.96%(-0.47)
Close16.00
4.78%(+0.73)
After HoursLast Updated: — ET
52W L: $8.3252W H: $16.91
$15.10
CHG-0.78 (-4.91%)
H$16.12
L$13.45
VOL14M
ASC (1h)
Ardmore Shipping Corporation · Industrials
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had excellent oral bioavailability, drug exposure and a half -life of up to 12 hours.
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks.
HAMILTON, Bermuda, March 6, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F") with the U.S. Securities and Exchange Commission (the "SEC"). In compliance with the New York Stock Exchange rules, a copy of the Form 20-F can be found in the Investor Relations section of the Company's website, www.ardmoreshipping.com, under SEC Filings.
Ardmore Shipping Corporation (NYSE: ASC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to
Ardmore Shipping Corporation (ASC) Analyst/Investor Day Transcript
HAMILTON, Bermuda, Feb. 12, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and twelve months ended December 31, 2025. Highlights and Recent Activity Reported Adjusted earnings of $11.6 million and net income attributable to common stockholders of $9.3 million for the three months ended December 31, 2025, or $0.28 Adjusted earnings per basic and diluted share, compared to Adjusted earnings of $10.3 million and net income attributable to common stockholders of $5.1 million, or $0.25 Adjusted earnings per basic and diluted share for the three months ended December 31, 2024.
O'Driscoll Aideen Siobhan
officer: SVP & Sr. Dir. of Corp. Svcs
0 SH @ $0.00
2026-03-18
O'Driscoll Aideen Siobhan
officer: SVP & Sr. Dir. of Corp. Svcs
6,596 SH @ $0.00
2027-03-01
Ruppelt Gernot
director, officer: Chief Executive Officer
0 SH @ $0.00
2026-03-18
Gaina Robert Cristian
officer: Chief Operating Officer
0 SH @ $0.00
2026-03-18
Ruppelt Gernot
director, officer: Chief Executive Officer
32,981 SH @ $0.00
2027-03-01
Gaina Robert Cristian
officer: Chief Operating Officer
7,915 SH @ $0.00
2027-03-01
Tikka Kirsi
director
0 SH @ $0.00
2026-03-18
Tikka Kirsi
director
8,155 SH @ $0.00
2026-06-17